Biogen’s Spinraza clocked up global sales of $1.72 billion for the company last year.
It is being reimbursed by numerous health systems across Europe - but to varying degrees.
The HSE told Biogen that it would not reimburse Spinraza at the price it was offering.
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team